Loading
  • News
  • Investors
  • Careers
  • Contact
  • X
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

About Us

We are a nimble rare disease therapeutics company with a proven record of bringing new therapies to patients.

Mission Statement

Employ creative, outside-the-box strategies to overcome drug development and regulatory challenges and bring life-changing therapeutics to people with rare diseases.

Vision Statement

To give every promising rare disease therapy candidate a fighting chance to reach patients and improve their quality of life.

Who We Are

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners and advocacy groups in all of our clinical and regulatory development strategies.

With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients.

Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.

The Zevra Story

Our Name

Zevra is Greek for zebra, the official symbol of rare disease. The idea came from the medical school adage, “when you hear hoofbeats, don’t expect a zebra,” meaning, illness is most likely caused by something common, not rare.

However, in a world of horses, we are paying attention to the zebras, people with rare diseases. In honor of our commitment, we named our company for them.

The distinct stripes of an individual zebra symbolize the many rare diseases represented by these patient communities.

To us, like the infinite, unique possibilities of a zebra’s stripes, we believe there are boundless pathways for therapeutics to achieve regulatory approval and reach people with rare diseases.

Our Background

From 2001 to 2004, Travis Mickle, Ph.D., led the team of scientists who invented Vyvanse®, a first-of-its-kind prodrug to address issues with the treatments that were then available for attention deficit hyperactive disorder (ADHD).

Leveraging their experience and expertise, Dr. Mickle, and Christal Mickle, M.A., founded KemPharm, Inc., a company that developed unique prodrugs, including two commercial products, using its proprietary Ligand Activated Therapy® technology platform.

After decades of experience in devising elegant prodrugs, the KemPharm team refocused their efforts on rare disease drug development and began to seek product candidates to treat rare diseases.

The company’s initial rare disease candidate was KP1077, an internally developed clinical-stage product candidate intended for the treatment of idiopathic hypersomnia (IH), a rare sleep disorder.

In May 2022, KemPharm acquired substantially all of the assets of Orphazyme, A/S, a Denmark-based company focused on neurological rare diseases, which included arimoclomol, a product candidate intended for the treatment of Niemann-Pick type C disease (NPC), and welcomed many of its team members, bolstering and expanding KemPharm’s development capabilities.

In February 2023, KemPharm became Zevra Therapeutics.

Leadership

Zevra is a team of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus with a proven record of bringing new therapies to patients.

Richard W. Pascoe

December 29, 2022
Chief Executive Officer & Board Member
https://zevra.com/wp-content/uploads/Zevra_Headshots-Rich.png 429 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:52:232023-03-17 12:36:10Richard W. Pascoe

Travis C. Mickle, Ph.D.

December 29, 2022
President & Board Member; Co-Founder
https://zevra.com/wp-content/uploads/Zevra_Headshots-Travis.png 429 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:45:372023-03-17 13:57:47Travis C. Mickle, Ph.D.

R. LaDuane Clifton, MBA, CPA

December 29, 2022
Chief Financial Officer, Secretary, & Treasurer
https://zevra.com/wp-content/uploads/Zevra_Headshots-LeDuane.png 429 320 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:52:422023-03-17 12:40:31R. LaDuane Clifton, MBA, CPA

Sven Guenther, Ph.D.

December 29, 2022
Chief Scientific Officer
https://zevra.com/wp-content/uploads/Zevra_Headshots-Sven.png 429 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:52:582023-03-17 12:40:51Sven Guenther, Ph.D.

Christal M.M. Mickle

December 29, 2022
Chief Product Development Officer; Co-Founder
https://zevra.com/wp-content/uploads/Zevra_Headshots-Christal.png 428 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:53:262023-03-17 12:42:07Christal M.M. Mickle

Joshua Schafer

January 30, 2023
Chief Commercial Officer & Executive Vice President, Business Development
https://zevra.com/wp-content/uploads/Zevra_Headshots-Josh.png 428 319 Ellie Solorio /wp-content/uploads/logo.svg Ellie Solorio2023-01-30 13:38:522023-03-17 12:42:38Joshua Schafer

Rene A. Braeckman, Ph.D.

December 29, 2022
Senior Vice President, Clinical Development
https://zevra.com/wp-content/uploads/Zevra_Headshots-Rene.png 428 320 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:54:202023-03-17 12:43:26Rene A. Braeckman, Ph.D.

Daniel Gallo, Ph.D.

February 3, 2023
Senior Vice President, Medical Affairs and Advocacy
https://zevra.com/wp-content/uploads/Zevra_Headshots-Dan.png 428 320 Ellie Solorio /wp-content/uploads/logo.svg Ellie Solorio2023-02-03 09:18:012023-03-17 12:44:30Daniel Gallo, Ph.D.

Christopher M. Lauderback, PhD

December 29, 2022
Senior Vice President, Manufacturing
https://zevra.com/wp-content/uploads/Zevra_Headshots-Christopher.png 428 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:54:022023-03-17 12:44:57Christopher M. Lauderback, PhD

Timothy Sangiovanni, CPA

December 29, 2022
Senior Vice President, Corporate Controller
https://zevra.com/wp-content/uploads/Zevra_Headshots-Timothy.png 428 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:54:392023-03-17 12:45:53Timothy Sangiovanni, CPA

Board of Directors

Matthew R. Plooster

December 29, 2022/in BOD/by eallison

Chairman of the Board

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:55:592023-02-16 13:12:35Matthew R. Plooster

Richard W. Pascoe

December 29, 2022/in BOD, Leadership/by eallison

Chief Executive Officer & Board Member

Read more
https://zevra.com/wp-content/uploads/Zevra_Headshots-Rich.png 429 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:52:232023-03-17 12:36:10Richard W. Pascoe

Travis C. Mickle, Ph.D.

December 29, 2022/in BOD, Leadership/by eallison

President & Board Member; Co-Founder

Read more
https://zevra.com/wp-content/uploads/Zevra_Headshots-Travis.png 429 319 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:45:372023-03-17 13:57:47Travis C. Mickle, Ph.D.

Tamara A. (Seymour) Favorito

December 29, 2022/in BOD/by eallison

Board Member & Chair, Audit & Compensation Committees

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:55:412023-02-16 12:48:01Tamara A. (Seymour) Favorito

Joseph B. Saluri

December 29, 2022/in BOD/by eallison

Board Member & Chair, Nominating & Corporate Governance Committee

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:56:352023-02-10 16:44:01Joseph B. Saluri

David S. Tierney, M.D.

December 29, 2022/in BOD/by eallison

Board Member

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:56:512023-03-21 16:56:06David S. Tierney, M.D.

Christopher Posner

December 29, 2022/in BOD/by eallison

Board Member

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2022-12-29 12:57:072023-02-10 16:49:53Christopher Posner
  • X
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2023 Zevra Therapeutics. All rights reserved. | Privacy Policy | Terms of Use

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only